Curexa

• Pharmacy Profile Name: Curexa Pharmacy
• Website: curexa.com
• Founded: 2003, as a family-owned pharmacy
• Location: Atlantic County, New Jersey
• Phone: 855-927-0390
• Pharmacist-in-Charge: Ryan (Director of Operations, 2018 Philadelphia College of Pharmacy graduate)
• Pharmacy Type: 503A state-licensed compounding pharmacy
• Accreditations: PCAB accredited + LegitScript certified
• GLP-1 Compounding: Semaglutide, Tirzepatide

About the Pharmacy

Founded in 2003 as a family-owned pharmacy, Curexa has grown into a leading provider of compounding, packaging, labeling, and digital and traditional pharmacy solutions for telemedicine and medical providers, veterinarians, manufacturers, and clinical research organizations across the nation. Unlike most pharmacies in this review series, Curexa’s business is almost entirely B2B — it serves healthcare providers and telehealth platforms rather than patients directly. That model has allowed it to grow quietly and consistently without the consumer-facing marketing controversies that have attracted regulatory attention to other compounders.

GLP-1 Compounding

Curexa compounds both semaglutide and tirzepatide as sterile injectables, fulfilling prescriptions through its telehealth and telemedicine provider network. GLP-1 compounding falls under Curexa’s broader sterile compounding capabilities, which cover hormones, dermatology, pediatrics, pain, men’s health, women’s health, mental health, and veterinary formulations.

Curexa’s process follows strict HIPAA and regulatory guidelines, which has allowed it to earn both PCAB accreditation and LegitScript certification. The PCAB accreditation is notable — it is a voluntary third-party quality credential from the Pharmacy Compounding Accreditation Board that requires pharmacies to demonstrate quality and safety practices beyond state board minimums. Very few compounders in the GLP-1 space hold it. No FDA Warning Letter was found for Curexa in the FDA’s public enforcement database as of March 2026.

Type of Pharmacy

Curexa’s designation as a 503A compounding pharmacy means it fills patient-specific medications through customized pharmacy solutions, giving patients the option for prescriptions free of fillers such as dyes, sugar, lactose, or alcohol. It is not a 503B outsourcing facility and does not produce bulk batches for distribution without patient-specific prescriptions.

Curexa’s compounding pharmacy is a non-sterile PCAB accredited facility — worth noting for patients receiving GLP-1 injectables, as sterile injectable compounding falls under a separate facility designation. Patients should confirm directly with their prescribing telehealth platform whether their specific GLP-1 formulation is compounded in a sterile-designated space.

States Licensed In

Curexa describes itself as a leading specialty compounding pharmacy serving patients’ unique needs with national reach through its telemedicine and fulfillment partnerships. A comprehensive state-by-state licensing list is not published publicly on Curexa’s website. Based on its B2B model servicing telehealth providers nationally, it ships across most or all states, but specific state licensing should be verified directly before prescription routing.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Telehealth Providers They Work With

Curexa operates as a B2B fulfillment pharmacy and does not publicly name its telehealth platform partners on its website. Curexa offers customized compounding services nationwide for telemedicine and medical providers, and its white-label solutions allow healthcare providers to personalize pharmaceutical products with their own brand identity. This white-label model means patients receiving medication from Curexa may not see the Curexa name on packaging at all — their telehealth provider’s branding may appear instead.

No confirmed telehealth platform partnerships for GLP-1 specifically were identified in public records. Patients who want to know whether their telehealth provider uses Curexa should ask their provider directly.

Pricing from Reviews

Curexa does not publish patient-facing pricing. As a fulfillment pharmacy operating through telehealth platforms, all pricing is set by the platform placing the prescription, not by Curexa. No consistent GLP-1 pricing data attributable specifically to Curexa-compounded medication was found in public patient reviews.

Overall Reviews

Curexa does not have a consumer-facing Trustpilot or Google Business review profile consistent with a direct-to-patient operation. Its B2B model means patient-facing reviews are rare — most feedback exists within the provider and healthcare partner community rather than on public consumer platforms.

The pharmacy’s credential stack — PCAB accreditation, LegitScript certification, 20+ years of operation, and no FDA enforcement history — places it among the more credentialed 503A compounders in this series. Its white-label model and deliberate low profile have kept it out of the regulatory crosshairs that higher-profile compounders attracted during the GLP-1 shortage era.